title: GISSI trial: early results and late follow-up. Gruppo Italiano per la Sperimentazione della Streptochinasi nell'Infarto Miocardico.
abstract: In the GISSI trial, 11,712 patients with acute myocardial infarction were randomized to receive either standard care or standard care with 1.5 million units streptokinase intravenously. A highly significant reduction in mortality during hospitalization in streptokinase-treated patients was observed. The mortality at 1 year was determined in 98.3% of the patients who had been originally randomized; the 1 year mortality of patients discharged alive was similar in those patients treated with streptokinase and those who were not; that is, the beneficial effects of streptokinase treatment on survival that were observed in the hospital phase of the study persisted unchanged and with comparable statistical significance for 1 year. However, a higher incidence of reinfarction occurred in the treated versus the control groups both during the hospital phase and at the 6 month follow-up. Streptokinase treatment had no detectable effect in patients with a history of previous infarction.
authors.affiliation: GISSI, Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Rovelli
authors.forename: C
authors.initials: C
authors.lastname: De Vita
authors.forename: G A
authors.initials: GA
authors.lastname: Feruglio
authors.forename: A
authors.initials: A
authors.lastname: Lotto
authors.forename: A
authors.initials: A
authors.lastname: Selvini
authors.forename: G
authors.initials: G
authors.lastname: Tognoni
mesh_terms: D002986:Clinical Trials as Topic; D005500:Follow-Up Studies; D006801:Humans; D007558:Italy; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D011897:Random Allocation; D012008:Recurrence; D013300:Streptokinase / Q000627:therapeutic use*
chemical_list: D013300:Streptokinase